Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Christoph Röllig, MD, MSc, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the measurement of residual disease in acute myeloid leukemia (AML), and the question of whether we should act therapeutically on MRD positivity in AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.